STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Molecular Biotechnological Research Original Research

In Silico Molecular Docking of Indigofera tinctoria Phytocompounds to Target EGFR/ERK and FGFR/FGF Pathway Proteins Involved in Prostate Cancer

  1. Nidhi Premanand Honavar Department of Biotechnology,Bangalore Indian Academy Degree College Autonomous, Hennur

Abstract

Objective: Prostate cancer being the second major cause of cancer-related deaths in males, affects the small walnut-shaped gland below the bladder called the prostate gland. The epidermal growth factor protein (EGFR), cascade protein (ERK), and fibroblast growth factor proteins (FGFR and FGF) are involved in the different signaling pathways that lead to the formation of different products, that are responsible for the progression of cancer and thus can be considered as the therapeutic targets. Indigofera tinctoria, a medicinal plant with proven anti-cancerous properties, was chosen for this study to investigate its different compound’s therapeutic effects against the target proteins, which are responsible for prostate cancer. Methods: In this study, 20 different compounds were selected from the Indigofera tinctoria plant as ligands to check for their binding affinity against the target proteins (EGFR, ERK, FGFR, and FGF). The docking of the ligands with the target proteins was done by using the PyRx Virtual tool. The computational investigation of all the ligands and the target proteins, such as their molecular structure, phytochemistry, therapeutic actions, and other data was carried out. The protein structure validation and the pharmacological evaluation of the ligands were done using the BIOVIA Discovery Studio, pdb sum generate, and ADMET lab 2.0, respectively. Result: The results of this study showed that the compounds, Pseudosemiglabrin, [(12S,15R,16R)-14,14-dimethyl-6-oxo-4-phenyl-3,11,13-trioxatetracyclo [8.6.0.02,7.012,16] hexadeca-1(10),2(7),4,8-tetraen-15-yl] acetate, Deguelin, Sumatrol and Rotenone showed good binding affinity with the target proteins and can be considered as a potential drug for the prostate cancer. Conclusion: The compounds selected were found to be active against the target proteins for prostate cancer and thus can be utilized for cancer suppression. Further in vitro studies need to be done to support this study.

Keywords

References (24)

  1. Rawla P. Epidemiology of Prostate Cancer. World Journal of Oncology. 2019;10(2):63-89. doi:10.14740/wjon1191
  2. Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M et al. FGF/FGFR signaling in health and disease. Signal Transduct Target Ther. 2020;5(1):181. doi:10.1038/s41392–020–00222–7.
  3. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2-16. doi:10.1016/j.gene.2005.10.018
  4. Uribe ML, Marrocco I, Yarden Y. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers. 2021;13(11):2748. doi:10.3390/cancers13112748
  5. Giacomini A, Grillo E, Rezzola S, Ribatti D, Rusnati M, Ronca R, et al. The FGF/FGFR system in the physiopathology of the prostate gland. Physiological Reviews. 2021;101(2):569-610. doi:10.1152/physrev.00005.2020
  6. Chen KL, Chang WSW, Cheung CHA, Lin CC, Huang CC, Yang YN, et al. Targeting cathepsin S induces tumor cell autophagy via the EGFR–ERK signaling pathway. Cancer Letters. 2012;317(1):89-98. doi:10.1016/j.canlet.2011.11.015
  7. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends in Genetics. 2004;20(11):563-569. doi:10.1016/j.tig.2004.08.007
  8. Lu Y, Liu B, Liu Y, Yu X, Cheng G. Dual effects of active ERK in cancer: A potential target for enhancing radiosensitivity (Review). Oncology Letters. 2020;20(2):993-1000. doi:10.3892/ol.2020.11684
  9. Motamarri NS, Karthikeyan M, Rajasekar S, Gopal V. Indigofera tinctoria Linn-a phytopharmacological review. Int J Res Pharm Biomed Sci. 2012;3(1):164–9.
  10. Thamilselvan V, Menon M, Thamilselvan S. Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase‐3 β/β‐catenin pathway. International Journal of Cancer. 2011;129(12):2916-2927. doi:10.1002/ijc.25949
  11. Ahmed Hassan LE, Khadeer Ahamed MB, Abdul Majid AS, Iqbal MA, Al Suede FSR, Haque RA, et al. Crystal Structure Elucidation and Anticancer Studies of (-)-Pseudosemiglabrin: A Flavanone Isolated from the Aerial Parts of Tephrosia apollinea. PLoS ONE. 2014;9(3):e90806. doi:10.1371/journal.pone.0090806
  12. Gerhäuser C, Mar W, Lee SK, Suh N, Luo Y, Kosmeder J et al. Rotenoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase. Nat Med. 1995;1(3):260–6. doi:10.1038/nm0395–260.
  13. Wei YF, Su J, Deng ZL, Zhu C, Yuan L, Lu ZJ, Zhu QY. [Indirubin inhibits the proliferation of prostate cancer PC-3 cells]. Zhonghua Nan Ke Xue. 2015 Sep;21(9):788–91. Chinese.
  14. Choi S, Choi Y, Tien Dat N, Hwangbo C, Lee JJ, Lee JH. Tephrosin induces internalization and degradation of EGFR and ErbB2 in HT-29 human colon cancer cells. Cancer Letters. 2010;293(1):23-30. doi:10.1016/j.canlet.2009.12.012
  15. Da J, Xu M, Wang Y, Li W, Lu M, Wang Z. Kaempferol Promotes Apoptosis While Inhibiting Cell Proliferation via Androgen-Dependent Pathway and Suppressing Vasculogenic Mimicry and Invasion in Prostate Cancer. Analytical Cellular Pathology. 2019;2019:1-10. doi:10.1155/2019/1907698
  16. Orton RJ, Adriaens ME, Gormand A, Sturm OE, Kolch W, Gilbert DR. Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway. BMC Syst Biol. 2009;3(1):100. doi:10.1186/1752–0509–3–100.
  17. Renukadevi KP, Sultana SS. Determination of Antibacterial, Antioxidant and Cytotoxicity Effect of Indigofera tinctoria on Lung Cancer Cell Line NCI-h69. International Journal of Pharmacology. 2011;7(3):356-362. doi:10.3923/ijp.2011.356.362
  18. Srinivasan N. Medicinal plants for cancer treatment: a review approach. Int J Biol, (Research). 2018;3(4):57–61.
  19. Szymczyk J, Sluzalska K, Materla I, Opalinski L, Otlewski J, Zakrzewska M. FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance. Cancers. 2021;13(22):5796. doi:10.3390/cancers13225796
  20. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Research. 2021;49(W1):W5-W14. doi:10.1093/nar/gkab255
  21. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993;118(10):793–803. doi:10.7326/0003–4819–118–10–199305150–00007.
  22. Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62(6):3-12. doi:10.1016/j.urology.2003.10.013
  23. Litwin MS, Tan HJ. The Diagnosis and Treatment of Prostate Cancer. JAMA. 2017;317(24):2532. doi:10.1001/jama.2017.7248
  24. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The Epidemiology of Prostate Cancer. Cold Spring Harbor Perspectives in Medicine. 2018;8(12):a030361. doi:10.1101/cshperspect.a030361